Press release
DelveInsight's Analyses Interstitial Cystitis Pipeline 2023 - FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Merck, Teva Pharmaceutical, Lipella Pharmaceuticals, Seikagaku Corporation, UCB
Interstitial Cystitis Pipeline
For Interstitial Cystitis Emerging drugs, the Interstitial Cystitis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Acute Pyelonephritis pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Request for Sample Pages: https://www.delveinsight.com/report-store/interstitial-cystitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Recent developments in the Interstitial Cystitis Pipeline:
• Glycologix, Inc. ("Glycologix"), a clinical-stage company focused on developing biopolymers for the protection and repair of soft tissues, today announced the treatment of the first patient in a pilot clinical study evaluating GLX-100 as a novel treatment for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). The multi-center pilot trial is designed to assess the safety, tolerability and effectiveness of GLX-100 in participants with IC/BPS and is expected to enroll up to 40 women with results anticipated in 2024.
• Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that the first patient has been enrolled in a 4-arm Phase 2 trial2 of AlenuraTM, comparing the product candidate to both of its individual components (heparin and lidocaine)3 as well as placebo. AlenuraTM is a patented, innovative, clinical-stage bladder instillation product candidate that combines lidocaine, a well-established anaesthetic, in a new alkalinized form with heparin, a glycoso-amino-glycan (GAG), a component of bladder mucous membranes.
Some of the key Interstitial Cystitis companies working in the market are:
• Merck & Co
• Teva Pharmaceutical Industries
• Integrative Therapeutics, Inc.
• Lipella Pharmaceuticals, Inc.
• Addex Therapeutics
• Seikagaku Corporation
• UCB
• Alivio Therapeutics
• Imbrium Therapeutics
• Ironwood Pharmaceuticals, And Many Others.
Learn more about the emerging Interstitial Cystitis pipeline therapies @ https://www.delveinsight.com/sample-request/interstitial-cystitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Interstitial cystitis Overview:
Interstitial cystitis (IC), also called bladder pain syndrome, is a chronic, or long-lasting, condition that causes painful urinary symptoms. Symptoms of IC may be different from person to person. For example, some people feel mild discomfort, pressure, or tenderness in the pelvic area. Other people may have intense pain in the bladder or struggle with urinary urgency, the sudden need to urinate, or frequency, the need to urinate more often. IC can occur at any age, including during childhood, but is most common in adult women and men. About twice as many women are affected as men. However, more men may struggle with IC than researchers originally thought. Some research suggests that women are more likely to develop IC if they have a history of being sexually abused or physically traumatized
Interstitial Cystitis Emerging Drugs
Certolizumab pegol: UCB
Certolizumab pegol (Cimzia) developed by UCB, Belgium is a recombinant, humanized F(ab)' fragment of an antibody conjugated to polyethylene glycol to enhance its plasma half-life. It is in phase 3 stage of development for the treatment of Interstitial cystitis.
SI-722: Seikagaku Corporation
SI-722 is a novel chemical compound in which a steroid is conjugated with chondroitin sulfate using Seikagaku's proprietary glycosaminoglycan modification technology and drug delivery systems (DDS). SI-722 injected into the bladder is thought to demonstrate long-lasting improvement in the conditions of frequent urination and bladder pain by releasing a steroid with an anti-inflammatory effect. SI-722 has completed a Phase I clinical study in the U.S. In November 2019, it is starting a Phase I/II clinical study. This clinical study will evaluate the drug for safety, tolerability, and pharamcokinetics, and will conduct an exploratory evaluation of its effectiveness.
Request a sample and discover the recent advances in Interstitial Cystitis treatment drugs @ https://www.delveinsight.com/sample-request/interstitial-cystitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Interstitial Cystitis Analytical Perspective by DelveInsight
• In-depth Interstitial Cystitis Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
• Interstitial Cystitis Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type, and MOA type across this indication.
Scope of the Interstitial Cystitis pipeline report
• The Interstitial Cystitis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Interstitial Cystitis across the complete product development cycle, including all clinical and nonclinical stages.
• It comprises of detailed profiles of Interstitial Cystitis therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
• Detailed Interstitial Cystitis research and development progress and trial details, results wherever available, are also included in the pipeline study.
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Interstitial Cystitis.
Dive deep into rich insights for new drugs for Interstitial Cystitis treatment, visit @ https://www.delveinsight.com/sample-request/interstitial-cystitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content:
Introduction
Executive Summary
Interstitial Cystitis: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Interstitial Cystitis Pipeline Therapeutics
• Comparative Analysis
Interstitial Cystitis Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Certolizumab pegol: UCB
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Interstitial Cystitis Preclinical and Discovery Stage Products
• Comparative Analysis
LYT 503: PureTech Health
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Interstitial Cystitis Products
• Comparative Analysis
Interstitial Cystitis Companies
Interstitial Cystitis Key Products
Interstitial Cystitis Unmet Needs
Interstitial Cystitis Market Drivers and Barriers
Interstitial Cystitis Future Perspectives and Conclusion
Interstitial Cystitis Analyst Views
Interstitial Cystitis Companies
Appendix
Dive deep into rich insights for new drugs for Interstitial Cystitis treatment, visit @ https://www.delveinsight.com/sample-request/interstitial-cystitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Chronic Pruritus Market: https://www.delveinsight.com/report-store/chronic-pruritus-market
• Foot And Ankle Devices Market: https://www.delveinsight.com/report-store/orthotic-devices-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Global Electrophysiology Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
Contact Us:
Ankit Nigam
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release DelveInsight's Analyses Interstitial Cystitis Pipeline 2023 - FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Merck, Teva Pharmaceutical, Lipella Pharmaceuticals, Seikagaku Corporation, UCB here
News-ID: 3327015 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Interstitial
Prominent Interstitial Cystitis Market Trend for 2025: Advancements in Interstit …
How Are the key drivers contributing to the expansion of the interstitial cystitis market?
The increasing occurrence of urinary tract infections is anticipated to fuel the expansion of the interstitial cystitis market. Urinary tract infections are bacterial infections that can materialize at any point in the urinary system, resulting from bacteria that infiltrate the urethra. These infections could directly or indirectly bring about bacterial cystitis, and lack of treatment can lead…
Shaping the Interstitial Cystitis Market in 2025: Advancements in Interstitial C …
How Big Is the Interstitial Cystitis Market Expected to Be, and What Will Its Growth Rate Be?
The interstitial cystitis market is projected to grow from $1.83 billion in 2024 to $1.98 billion in 2025, with a compound annual growth rate (CAGR) of 8.2%. This growth is attributed to advancements in diagnosis, increased awareness and education, pharmaceutical developments, and supportive therapies.
The Interstitial Cystitis market will grow to $2.78 billion by 2029…
Prominent Interstitial Lung Disease Market Trend for 2025: Innovative Drug Devel …
What Are the Projected Growth and Market Size Trends for the Interstitial Lung Disease Market?
The interstitial lung disease market is expected to grow from $1.97 billion in 2024 to $2.11 billion in 2025, at a CAGR of 7.2%. Growth drivers include improved awareness and diagnosis, immune system modulation therapies, respiratory rehabilitation programs, and multidisciplinary care teams.
The Interstitial Lung Disease market will grow to $2.85 billion by 2029 at a CAGR…
Interstitial lung disease Pipeline involves 120+ key companies continuously work …
DelveInsight's, "Interstitial Lung Diseases Pipeline Insight, 2022," report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Interstitial Lung Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Interstitial Lung Disease…
Global Interstitial Pneumonia Market Growth 2020-2025
Global Interstitial Pneumonia Market Overview:
The global Interstitial Pneumonia market is expected to grow at a significant pace, reports GLOBAL INFO RESEARCH. Its latest research report, titled [Global and United States Interstitial Pneumonia Market 2020 by Company, Type and Application, Forecast to 2025], offers a unique point of view about the global market. Analysts believe that the changing consumption patterns are expected to have a great influence on the overall market. For a…
Interstitial Lung Disease Therapeutics - Pipeline Analysis 2018
Interstitial lung disease is a type of inflammatory disease that affects and thickens the interstitium of the lungs.
Download the sample report @ https://www.pharmaproff.com/request-sample/1126
The interstitium is a lace like network of the tissue that provide support to the air sacs and the capillaries in the interstitium which allows the gas exchange between the blood and alveolar tissues.
Get the detailed analysis @ https://www.pharmaproff.com/report/interstitial-lung-disease-therapeutics-pipeline-analysis
Some of the types of the condition include…
